Copyright Reports & Markets. All rights reserved.

Global Antiretroviral Agent Market Growth 2021-2026

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Antiretroviral Agent Consumption 2016-2026
    • 2.1.2 Antiretroviral Agent Consumption CAGR by Region
  • 2.2 Antiretroviral Agent Segment by Type
    • 2.2.1 Nucleoside Reverse Transcriptase Inhibitors
    • 2.2.2 Protease Inhibitors
    • 2.2.3 HIV Integrase Strand Transfer Inhibitors
    • 2.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 2.2.5 Entry Inhibitors—CCR5 Co-Receptor Antagonist
    • 2.2.6 Fusion Inhibitors
    • 2.2.7 Others
  • 2.3 Antiretroviral Agent Sales by Type
    • 2.3.1 Global Antiretroviral Agent Sales Market Share by Type (2016-2021)
    • 2.3.2 Global Antiretroviral Agent Revenue and Market Share by Type (2016-2021)
    • 2.3.3 Global Antiretroviral Agent Sale Price by Type (2016-2021)
  • 2.4 Antiretroviral Agent Segment by Application
    • 2.4.1 Hospital Pharmacies
    • 2.4.2 Retail Pharmacies
    • 2.4.3 Online Pharmacies
    • 2.4.4 Others
  • 2.5 Antiretroviral Agent Sales by Application
    • 2.5.1 Global Antiretroviral Agent Sale Market Share by Application (2016-2021)
    • 2.5.2 Global Antiretroviral Agent Revenue and Market Share by Application (2016-2021)
    • 2.5.3 Global Antiretroviral Agent Sale Price by Application (2016-2021)

3 Global Antiretroviral Agent by Company

  • 3.1 Global Antiretroviral Agent Sales Market Share by Company
    • 3.1.1 Global Antiretroviral Agent Sales by Company (2019-2021)
    • 3.1.2 Global Antiretroviral Agent Sales Market Share by Company (2019-2021)
  • 3.2 Global Antiretroviral Agent Revenue Market Share by Company
    • 3.2.1 Global Antiretroviral Agent Revenue by Company (2019-2021)
    • 3.2.2 Global Antiretroviral Agent Revenue Market Share by Company (2019-2021)
  • 3.3 Global Antiretroviral Agent Sale Price by Company
  • 3.4 Global Manufacturers Antiretroviral Agent Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Antiretroviral Agent Product Location Distribution
    • 3.4.2 Players Antiretroviral Agent Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 Antiretroviral Agent by Region

  • 4.1 Global Antiretroviral Agent by Region
    • 4.1.1 Global Antiretroviral Agent Sales by Region
    • 4.1.2 Global Antiretroviral Agent Revenue by Region
  • 4.2 Americas Antiretroviral Agent Sales Growth
  • 4.3 APAC Antiretroviral Agent Sales Growth
  • 4.4 Europe Antiretroviral Agent Sales Growth
  • 4.5 Middle East & Africa Antiretroviral Agent Sales Growth

5 Americas

  • 5.1 Americas Antiretroviral Agent Sales by Country
    • 5.1.1 Americas Antiretroviral Agent Sales by Country (2016-2021)
    • 5.1.2 Americas Antiretroviral Agent Revenue by Country (2016-2021)
  • 5.2 Americas Antiretroviral Agent Sales by Type
  • 5.3 Americas Antiretroviral Agent Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Antiretroviral Agent Sales by Region
    • 6.1.1 APAC Antiretroviral Agent Sales by Region (2016-2021)
    • 6.1.2 APAC Antiretroviral Agent Revenue by Region (2016-2021)
  • 6.2 APAC Antiretroviral Agent Sales by Type
  • 6.3 APAC Antiretroviral Agent Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Antiretroviral Agent by Country
    • 7.1.1 Europe Antiretroviral Agent Sales by Country (2016-2021)
    • 7.1.2 Europe Antiretroviral Agent Revenue by Country (2016-2021)
  • 7.2 Europe Antiretroviral Agent Sales by Type
  • 7.3 Europe Antiretroviral Agent Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Antiretroviral Agent by Country
    • 8.1.1 Middle East & Africa Antiretroviral Agent Sales by Country (2016-2021)
    • 8.1.2 Middle East & Africa Antiretroviral Agent Revenue by Country (2016-2021)
  • 8.2 Middle East & Africa Antiretroviral Agent Sales by Type
  • 8.3 Middle East & Africa Antiretroviral Agent Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Country

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers and Impact
    • 9.1.1 Growing Demand from Key Regions
    • 9.1.2 Growing Demand from Key Applications and Potential Industries
  • 9.2 Market Challenges and Impact
  • 9.3 Market Trends

10 Marketing, Distributors and Customer

  • 10.1 Sales Channel
    • 10.1.1 Direct Channels
    • 10.1.2 Indirect Channels
  • 10.2 Antiretroviral Agent Distributors
  • 10.3 Antiretroviral Agent Customer

11 Global Antiretroviral Agent Market Forecast

  • 11.1 Global Antiretroviral Agent Forecast by Region
    • 11.1.1 Global Antiretroviral Agent Forecast by Regions (2021-2026)
    • 11.2.2 Global Antiretroviral Agent Revenue Forecast by Regions (2021-2026)
  • 11.2 Americas Forecast by Country
  • 11.3 APAC Forecast by Region
  • 11.4 Europe Forecast by Country
  • 11.5 Middle East & Africa Forecast by Country
  • 11.6 Global Antiretroviral Agent Forecast by Type
  • 11.7 Global Antiretroviral Agent Forecast by Application

12 Key Players Analysis

  • 12.1 ViiV Healthcare
    • 12.1.1 ViiV Healthcare Company Information
    • 12.1.2 ViiV Healthcare Antiretroviral Agent Product Offered
    • 12.1.3 ViiV Healthcare Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.1.4 ViiV Healthcare Main Business Overview
    • 12.1.5 ViiV Healthcare Latest Developments
  • 12.2 Gilead Sciences
    • 12.2.1 Gilead Sciences Company Information
    • 12.2.2 Gilead Sciences Antiretroviral Agent Product Offered
    • 12.2.3 Gilead Sciences Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.2.4 Gilead Sciences Main Business Overview
    • 12.2.5 Gilead Sciences Latest Developments
  • 12.3 GlaxoSmithKline
    • 12.3.1 GlaxoSmithKline Company Information
    • 12.3.2 GlaxoSmithKline Antiretroviral Agent Product Offered
    • 12.3.3 GlaxoSmithKline Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.3.4 GlaxoSmithKline Main Business Overview
    • 12.3.5 GlaxoSmithKline Latest Developments
  • 12.4 Merck Sharp and Dohme
    • 12.4.1 Merck Sharp and Dohme Company Information
    • 12.4.2 Merck Sharp and Dohme Antiretroviral Agent Product Offered
    • 12.4.3 Merck Sharp and Dohme Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.4.4 Merck Sharp and Dohme Main Business Overview
    • 12.4.5 Merck Sharp and Dohme Latest Developments
  • 12.5 Bristol-Myers Squibb
    • 12.5.1 Bristol-Myers Squibb Company Information
    • 12.5.2 Bristol-Myers Squibb Antiretroviral Agent Product Offered
    • 12.5.3 Bristol-Myers Squibb Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.5.4 Bristol-Myers Squibb Main Business Overview
    • 12.5.5 Bristol-Myers Squibb Latest Developments
  • 12.6 Janssen Pharmaceuticals
    • 12.6.1 Janssen Pharmaceuticals Company Information
    • 12.6.2 Janssen Pharmaceuticals Antiretroviral Agent Product Offered
    • 12.6.3 Janssen Pharmaceuticals Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.6.4 Janssen Pharmaceuticals Main Business Overview
    • 12.6.5 Janssen Pharmaceuticals Latest Developments
  • 12.7 Pfizer
    • 12.7.1 Pfizer Company Information
    • 12.7.2 Pfizer Antiretroviral Agent Product Offered
    • 12.7.3 Pfizer Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.7.4 Pfizer Main Business Overview
    • 12.7.5 Pfizer Latest Developments
  • 12.8 Boehringer Ingelheim
    • 12.8.1 Boehringer Ingelheim Company Information
    • 12.8.2 Boehringer Ingelheim Antiretroviral Agent Product Offered
    • 12.8.3 Boehringer Ingelheim Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.8.4 Boehringer Ingelheim Main Business Overview
    • 12.8.5 Boehringer Ingelheim Latest Developments
  • 12.9 AbbVie
    • 12.9.1 AbbVie Company Information
    • 12.9.2 AbbVie Antiretroviral Agent Product Offered
    • 12.9.3 AbbVie Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.9.4 AbbVie Main Business Overview
    • 12.9.5 AbbVie Latest Developments
  • 12.10 Genentech
    • 12.10.1 Genentech Company Information
    • 12.10.2 Genentech Antiretroviral Agent Product Offered
    • 12.10.3 Genentech Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.10.4 Genentech Main Business Overview
    • 12.10.5 Genentech Latest Developments
  • 12.11 Mylan
    • 12.11.1 Mylan Company Information
    • 12.11.2 Mylan Antiretroviral Agent Product Offered
    • 12.11.3 Mylan Antiretroviral Agent Sales, Revenue, Price and Gross Margin (2019-2021)
    • 12.11.4 Mylan Main Business Overview
    • 12.11.5 Mylan Latest Developments

13 Research Findings and Conclusion

According to this latest study, the 2021 growth of Antiretroviral Agent will have significant change from previous year. By the most conservative estimates of global Antiretroviral Agent market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ million in 2020. Over the next five years the Antiretroviral Agent market will register a % CAGR in terms of revenue, the global market size will reach US$ million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Antiretroviral Agent market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors—CCR5 Co-Receptor Antagonist
Fusion Inhibitors
Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
ViiV Healthcare
Gilead Sciences
GlaxoSmithKline
Merck Sharp and Dohme
Bristol-Myers Squibb
Janssen Pharmaceuticals
Pfizer
Boehringer Ingelheim
AbbVie
Genentech
Mylan
Buy now